Aarti Drugs
Aarti Drugs Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #52 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Aarti Drugs targets 10%-15% volume growth over the next two years, driven by existing product capacity and new expansions (Page 12). Aarti Drugs expects sustained growth momentum driven by ongoing capacity expansion and operational excellence.
From Aarti Drugs's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Aarti Drugs targets 10%-15% volume growth over the next two years, driven by existing product capacity and new expansions (Page 12).
- Volume growth is expected even if the salicylic acid derivatives segment does not pick up immediately (Page 12).
- The Sayakha facility ramp-up will significantly increase captive consumption, supporting volume and margin growth (Page 13).
- Pricing pressures are expected to ease, potentially boosting demand and volume growth in upcoming quarters (Page 10).
- Focus on increasing sales in regulated markets (US, Europe) with new USFDA and CEP approvals is expected to expand higher-margin revenues (Page 12).
- Specialty chemical segment saw 149% growth and is expected to sustain or improve performance going forward (Page 8).
2 more points from Aarti Drugs's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Drugs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company recently completed a capital expenditure of INR 600 crores focused on Phase 1 greenfield facilities, achieving an asset turnover of around 1.5x.
- Phase 2 brownfield capex is planned for Sayakha and G61 Tarapur sites, expected to deliver higher asset turnover of 3x to 4x due to existing infrastructure.
- Expansion underway at Baddi facility to nearly double oral solid dosage manufacturing capacity.
- Construction of additional USFDA-approved Metformin capacity (500+ tons/month) at Sarigam, expected to take 10-12 months to complete.
- Plans for a quasi greenfield USFDA plant adjacent to the current USFDA facility to more than double production capacity with 3 new multipurpose lines are underway.
2 more points from Aarti Drugs's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Drugs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Aarti Drugs's call on order book
Create a free account to keep reading this call
Aarti Drugs — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹720 Cr, net profit ₹55 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Drugs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Drugs and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Drugs Q1 FY27 results?
Aarti Drugs targets 10%-15% volume growth over the next two years, driven by existing product capacity and new expansions (Page 12). Aarti Drugs expects sustained growth momentum driven by ongoing capacity expansion and operational excellence.
What is Aarti Drugs share price analysis?
Aarti Drugs currently shows a below-average growth signal. The stock trades at a P/E of 19.8 with a market cap of ₹3,810 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Drugs planning capital expenditure?
The company recently completed a capital expenditure of INR 600 crores focused on Phase 1 greenfield facilities, achieving an asset turnover of around 1.5x.
Keep Aarti Drugs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.